Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: An analysis of the JSHCT

M. Murata, T. Nishida, S. Taniguchi, K. Ohashi, H. Ogawa, T. Fukuda, T. Mori, H. Kobayashi, C. Nakaseko, N. Yamagata, Y. Morishima, T. Nagamura-Inoue, H. Sakamaki, Y. Atsuta, R. Suzuki, T. Naoe

研究成果: Article査読

24 被引用数 (Scopus)

抄録

To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.

本文言語English
ページ(範囲)355-360
ページ数6
ジャーナルBone Marrow Transplantation
49
3
DOI
出版ステータスPublished - 2014 3月
外部発表はい

ASJC Scopus subject areas

  • 血液学
  • 移植

フィンガープリント

「Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: An analysis of the JSHCT」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル